AdjuTec Pharma AS – 3rd place winner of the Poster Competition at the 9th AMR Conference in Basel, with the poster APC148: A Safe, Selective, and Efficient Metallo-β-Lactamase Inhibitor – has recently successfully completed it’s First-in-Human study with our specific metallo-ß-lactamase (MBL) inhibitor APC148 in a total of 46 volunteers. The study was designed as a placebo-controlled Single-Ascending-Dose study, including six dose levels. The study showed linear pharmacokinetics at all dose levels with an average half-life of 2.6 hours. APC148 was infused over three hours and only local mild events were reported.

APC148 is targeting all MBLs and will be combined with broad-spectrum antibiotics and an SBL-inhibitor to offer an effective and safe product for patients with severe infections at risk of harboring MBL-producing pathogens. In an in vitro screening program of 176 MBL-producing Enterobacterales we tested meropenem and  cefepime combined with APC148 and an SBL-inhibitor. Both APC148 products were more potent than all comparators. The results from the APC148 phase 1 SAD study presented at ESCMID in Vienna is very encouraging and a first step of our clinical journey to document safety and efficacy of this platform MBL-inhibitor technology.

A post by AdjuTec Pharma AS

Just like AdjuTec Pharma AS, INCATE encourages all the members of our community to share their exciting opportunities, connections, and milestones. We’d love to hear from you!

Reach out to us at comms@incate.net and let us know what you’ve been up to.